{{Rsnum
|rsid=2254958
|Gene=EIF2AK2
|Chromosome=2
|position=37149148
|Orientation=plus
|GMAF=0.4316
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=EIF2AK2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 35.4 | 49.6 | 15.0
| HCB | 9.5 | 35.8 | 54.7
| JPT | 0.0 | 30.1 | 69.9
| YRI | 85.7 | 12.9 | 1.4
| ASW | 68.4 | 24.6 | 7.0
| CHB | 9.5 | 35.8 | 54.7
| CHD | 8.3 | 31.2 | 60.6
| GIH | 46.5 | 42.6 | 10.9
| LWK | 89.1 | 10.0 | 0.9
| MEX | 32.8 | 58.6 | 8.6
| MKK | 72.4 | 26.9 | 0.6
| TSI | 33.3 | 54.9 | 11.8
| HapMapRevision=28
}}While the [[ApoE4]] allele ([[rs429358(C)]]) is widely accepted as the predominant genetic risk factor for [[Alzheimer's disease]], there are likely to be numerous other factors, both genetic and environmental, associated to lesser degrees with susceptibility to the disease. Genes influencing the immune system, and in particular susceptibility to viral infections such as [[herpes]], may be among such factors. {{PMID|16406033}}

This SNP, located in the promoter region of the [[EIF2AK2]] gene and thus implicated in the activation of [[HIV]] and [[HSV-1]] viruses, is seen more commonly in ~300 [[Alzheimer]] patients than in the same number of controls. The risk allele is [[rs2254958(C)]]. The odds ratio is reported to be 1.61 (CI: 1.02-2.55) for [[rs2254958(C;C)]] homozygotes, and 1.24 (CI: 0.80-1.93) for [[rs2254958(C;T)]] heterozygotes, compared with [[rs2254958(T;T)]] homozygotes. {{PMID|17420072}}

{{PMID Auto
|PMID=15726497
|Title=Gene-environment interaction effects on the development of immune responses in the 1st year of life.
|OA=1
}}

{{PMID Auto
|PMID=19434718
|Title=Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|OA=1
}}

{{PMID Auto
|PMID=19604093
|Title=Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}